Tango Therapeutics is a clinical-stage company developing vopimetostat, an oral PRMT5 inhibitor for cancers missing the MTAP gene, led by pancreatic cancer; it is not approved.
Tango's investment case centers on vopimetostat, an investigational PRMT5 inhibitor, plus daraxonrasib in MTAP-deleted pancreatic cancer. Updated Phase 1/2 results show 82% ORR and 88% nine-month PFS in previously treated patients. A randomized front-line Phase 3 against chemotherapy is planned for the first half of 2027. Lung monotherapy and TNG456 data could broaden the franchise. Cash was $1.0 billion at June 30, 2026; management's funding guidance into 2030 depends on its operating plan.
Thesis checklist
0 risks need attention
Why it is in this state
The evidence, what would weaken it and the source filing
Why it is in this state
The evidence, what would weaken it and the source filing
Why it is in this state
The evidence, what would weaken it and the source filing
Why it is in this state
The evidence, what would weaken it and the source filing
Next decision point
Tests: A front-line Phase 3 design is agreed
Does the planned chemotherapy-controlled design become the final registrational trial, with partner supply secured and initiation on schedule?
Strong, inconclusive and weak outcomes
What to look for in the result and how each would move the checklist
Price and material events
Select an event marker to read the update below. Marker colors show Thesis status.
Tango plans front-line Phase 3 as pancreatic combination responses show longer durability
Vopimetostat's 92% ORR in MTAP-deleted PDAC drives a registrational Phase 3 bet; whether that signal survives randomization against standard of care determines the thesis
Vopimetostat's 92% ORR in MTAP-deleted PDAC drives Phase 3 ambitions; whether that signal holds in a randomized trial defines the thesis
TNG462's registrational trial in MTAP-deleted pancreatic cancer tests whether Phase 1/2 PFS and safety signals translate into regulatory approval
About this history: every entry shows when the Thesis moved and what it said. The reasoning behind each move (the evidence, the analysis and the source filing) and the earnings write-ups are part of a subscription.
Dates, trials and completed outcomes are open to everyone. What each upcoming milestone hinges on is part of a subscription.
Disease areas: Lung cancer, Gastrointestinal cancers, Other cancers
Catalyst calendar · Upcoming FDA decisions · Thesis changes
Competitive landscape
13 peers tracked
Cash: Market-data provider estimate; measurement period unavailable.
Debt: Market-data provider estimate; a complete comparable filing balance is unavailable.
Quarterly burn: Estimated from trailing free cash flow; measurement period unavailable.
Net cash and estimated runway require verified matching measurement periods. Missing debt components are not assumed to be zero.
Runway: No underlying guidance available.